Stargardt Disease and Regenerative Medicine Research

Last medically reviewed: October 7, 2026

⚠ Important — educational information only, not medical advice

EyeCyte provides educational and scientific information and does not provide medical advice, diagnosis, or treatment. Emerging regenerative and biologic technologies discussed on this website may be experimental, investigational, unapproved, or supported only by preclinical evidence. Patients should discuss medical decisions with appropriately licensed healthcare professionals.
Not an FDA-approved treatment unless explicitly stated. Except where a page names an FDA-approved product, the stem-cell, MSC, exosome, extracellular-vesicle, Wharton’s jelly and other biologic approaches described here are not FDA-approved for any eye condition. Research findings — especially laboratory and animal studies — are not proof that anything works or is safe in people.
Research-Use-Only (RUO): Research-Use-Only (RUO) materials referenced on EyeCyte are for laboratory research by qualified professionals only. They are not drugs, biologics or devices approved for human use, are not intended for administration to people, and are not intended to diagnose, treat, cure, mitigate or prevent any disease.
EyeCyte does not sell, offer, recommend or refer for treatment. Be cautious of any clinic offering unapproved stem-cell or biologic injections for the eye; the FDA has warned of serious harm, including blindness.

Full medical disclaimer · RUO policy · Medical review policy

What is stargardt disease?

Stargardt disease is an inherited macular dystrophy, most often caused by variants in the ABCA4 gene. It typically begins in childhood or early adulthood and causes progressive loss of central vision.

What causes stargardt disease?

Most cases are inherited in an autosomal recessive pattern. Researchers study how the accumulation of byproducts of the visual cycle damages RPE cells and photoreceptors.

What structures or cells are affected?

The retinal pigment epithelium and photoreceptors of the macula.

How is stargardt disease currently treated or managed?

● Established / Approved

Diagnosis and genetic testing through a retina or inherited-retinal-disease specialist.
Protection from bright light and avoidance of vitamin A supplements unless a clinician advises otherwise.
Low-vision rehabilitation.

Are these approaches FDA approved for stargardt disease?

We are not aware of any FDA-approved treatment for Stargardt disease as of our last review, and no cell or biologic product is approved for it. Confirm current status with a specialist.^[2]

Why are researchers studying regenerative approaches?

Because Stargardt disease involves loss of RPE cells and photoreceptors, it has been included in cell-replacement research alongside AMD.

Research is not treatment. The studies summarized below are investigational. They are presented for education only, do not show that any approach is safe or effective in patients, and are not a recommendation. Unless stated as FDA-approved, none of these approaches is approved for this condition. RUO materials are not for human use.